Blueprint Medicines patents expiration
1. Ayvakit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(10 years from now) | |
| US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(10 years from now) | |
| US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(10 years from now) | |
| US11827642 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-863) | Jun 16, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 09, 2025 |
| New Indication(I-864) | Jun 16, 2024 |
| Orphan Drug Exclusivity(ODE-356) | Jun 16, 2028 |
| Orphan Drug Exclusivity(ODE-434) | May 22, 2030 |
| Orphan Drug Exclusivity(ODE-366) | Jan 09, 2027 |
| New Indication(I-912) | May 22, 2026 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 10 January, 2024
Market Authorisation Date: 16 June, 2021
Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...
Dosage: TABLET;ORAL
More Information on Dosage
AYVAKIT family patents
